BCL2L1 and malignant colon neoplasm: However, given the feasibility of AS oligonucleotide administration reported from first clinical trials (Jansen and Zangemeister-Wittke, 2002), the results reported here may provide the basis for the use of Bcl-xL AS oligonucleotides as a rational radiosensitising strategy to help improve treatment outcome in colon cancer patients.